GeoVax Labs Inc
GOVX
查看详细走势图
2.670USD
+0.090+3.49%
收盘 02/06, 16:00（美东）报价延迟15分钟
3.17M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.49%
5天
-4.64%
1月
-42.21%
6月
+293.23%
今年开始到现在
-37.54%
1年
+57.06%
查看详细走势图
TradingKey GeoVax Labs Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
GeoVax Labs Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名127/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价232.50。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
GeoVax Labs Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
GeoVax Labs Inc亮点
亮点风险
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
业绩高增长
公司营业收入稳步增长，连续3年增长4750.69%
业绩增长期
公司处于发展阶段，最新年度总收入3.95M美元
利润高增长
公司净利润处于行业前列，最新年度总收入3.95M美元
估值高估
公司最新PE估值-0.08，处于3年历史高位
机构加仓
最新机构持股139.37K股，环比增加41.89%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值9.77K
分析师目标
根据
4
位分析师
买入
评级
232.500
目标均价
+8144.68%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
GeoVax Labs Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
GeoVax Labs Inc简介
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
公司代码GOVX
公司GeoVax Labs Inc
CEODodd (David A)
网址https://www.geovax.com/
相关品种
